Introduction
============

Obesity is an increasing public health problem worldwide. The prevalence of obesity (body mass index \>30), among middle aged Europeans has been estimated as 15-20%.[@ref1] Data for the prevalence of morbid obesity (body mass index \>40) are lacking in Europe. In the United States, at least 5% of the population is morbidly obese.[@ref2] It is now recognised that surgical treatment is the most effective route to weight loss for people with morbid obesity, accompanied by reduction of mortality and improvement of comorbid conditions.[@ref3] [@ref4] [@ref5]

Bariatric surgical procedures (conventionally grouped as restrictive or malabsorptive) negatively affect bone remodelling, as suggested by studies on bone resorption markers, and bone mineral density. Restrictive procedures, such as vertical banded gastroplasty and laparoscopic adjustable banding, have been consistently reported to increase bone resorption,[@ref6] [@ref7] [@ref8] [@ref9] [@ref10] [@ref11] an increase that is similar in magnitude to that observed in other forms of weight reduction.[@ref8] The mechanisms behind the increase in bone resorption after weight loss are not fully understood, but two factors seem to be involved.

Firstly, reduced fat volume may lead to a reduction in circulating concentrations of oestrogens, which are partly synthesised in adipose tissue.[@ref10] Secondly, a fall in leptin could result in an increase in osteoclast recruitment and bone turnover.[@ref12] [@ref13] Malabsorptive procedures such as jejuno-ileal bypass and bilio-pancreatic diversion have also been associated with an increase of bone resorption and a decrease in bone mineral density[@ref14] [@ref15] [@ref16] [@ref17] [@ref18] [@ref19]; contributory factors clearly include calcium and vitamin D malabsorption, and secondary hyperparathyroidism.[@ref20] The Roux-en-Y gastric bypass surgery (a combined restrictive and malabsorptive operation) is also associated with increased bone resorption and decreased bone mineral density.[@ref14] [@ref21] [@ref22] [@ref23] [@ref24] [@ref25] [@ref26] [@ref27]

Although evidence indicates that patients may have decreased bone mineral density after bariatric surgery, the effect of the procedure on fracture risk has not been determined. Furthermore, the link between change in body mass index and fracture risk is unknown. Therefore, the aims of this study were to estimate the risk of fracture in patients with bariatric surgery compared with morbidly obese patients who did not undergo surgery, and to quantify the influence of the magnitude of body mass index decrease after surgery on fracture risk.

Methods
=======

Study population
----------------

A retrospective cohort study was conducted within the General Practice Research Database, now known as the Clinical Practice Research Datalink ([www.cprd.com](http://www.cprd.com/)). The Clinical Practice Research Datalink contains computerised medical records of 625 primary care practices in the United Kingdom, representing 8% of the population. The database provides detailed information on demographics, drug prescriptions, clinical events, specialist referrals, and hospital admissions. Previous studies using the database have shown a high level of data validity with respect to the reporting of fractures (\>90% of fractures were confirmed),[@ref28] and several systematic reviews have reported high degrees of validity and completeness of other diagnoses or smoking status.[@ref29] [@ref30] [@ref31]

The study population consisted of all patients with a Clinical Practice Research Datalink read code for bariatric surgery during the period of valid data collection (from January 1987 to December 2010). Gastrointestinal surgery for cancer was excluded in this study, because cancer itself could influence bone metabolism. The index date was defined as the first record for bariatric surgery. Bariatric surgery patients were only included if they had a body mass index record with a value of at least 30 at some point before surgery. Bariatric surgery patients were stratified by surgical technique, including adjustable gastric banding, Roux-en-Y gastric bypass, and other techniques (for example, gastrectomy, and malabsorptive procedures).

Selection of controls
---------------------

Each patient was matched by age, sex, body mass index (within a 10% difference), calendar time, and practice to up to six patients without a history of bariatric surgery (at any time during the study period). Body mass index entries were selected as the latest record before surgery (measured at any time before the index date).

Outcomes
--------

We followed up patients from the index date to either the end of data collection, the date of transfer of the patient out of the practice area, the patient's death, or fracture (Clinical Practice Research Datalink read codes), whichever came first. Fracture type was stratified according to World Health Organization definitions into osteoporotic fracture (spine, hip, forearm, or humerus) and non-osteoporotic fracture.[@ref32] [@ref33] For the analyses of these two different fracture groups, we followed up all patients for the occurrence of a fracture in the specific group, regardless of whether a fracture had already occurred in the other group (that is, patients could have sustained both an osteoporotic and non-osteoporotic fracture).

Potential confounders
---------------------

General risk factors considered in this study included age, sex, smoking status (a record of currently smoking, ex-smoker, or never smoked before; missing data were treated as a separate category in the analyses), a record of falls in the previous 6-12 months (any fall recorded by the general practitioner; falls in the previous six months were excluded), history of fracture, history of a chronic disease (cerebrovascular disease, heart failure, inflammatory bowel disease, asthma or chronic obstructive pulmonary disease, anaemia, and dementia), and a prescription in the previous six months for glucocorticosteroids, antiobesity drugs, calcium or vitamin D supplements, antihypertensive drugs, loop diuretics, hypnotics or anxiolytics, antipsychotics, antidepressants, proton pump inhibitors, or antiepileptic substances, and drugs for Parkinson's disease treatment.[@ref34] [@ref35] [@ref36] [@ref37] Age and the most recent record of body mass index before the index date were handled as continuous variables in the analyses.

Statistical analysis
--------------------

We conducted two main analyses using stratified Cox proportional hazards models (SAS 9.2, PHREG procedure; stratified matched cohort analysis). The first analysis compared the fracture rate in patients with bariatric surgery with that in control patients (with the same body mass index), to yield an estimate of the relative risk of fracture in bariatric surgery patients (stratified by type of fracture and type of bariatric surgical technique). We divided the total follow-up period into 30 day intervals. The presence of risk factors was assessed by reviewing the computerised medical records of risk factors before the start of an interval. We included potential confounders in the final model if they independently changed the β coefficient for bariatric surgery by at least 10%.

The second analysis studied the effect of excess loss in body mass index after surgery on fracture risk (with the limit of normality defined as body mass index of 25). For that purpose, we divided all patients with bariatric surgery into four different groups: those with no excess loss after surgery, those with 0-50% excess loss after surgery, those with at least 50% excess loss after surgery, and those whose amount of excess loss was unknown. We calculated excess loss as follows: 100×(preoperative body mass index−present body mass index)÷(preoperative body mass index−25). Based on this excess loss, person time was allocated to one of these four defined categories. In the event of no body mass index assessments in that specific period, the person time was allocated to the category in which excess loss was unknown.

We examined timing of fracture occurrence after bariatric surgery by including time interaction terms (time period×bariatric surgery) into the model for the following time intervals: less than three months, three to 12 months, one to two years, two to five years, and more than five years. Using smoothing spline regression,[@ref38] we visualised the time trend for risk of fracture for these given time intervals.

In a sensitivity analysis, we restricted bariatric surgery patients to those with a body mass index record within two months before bariatric surgery, and reset the index date for controls as the date of most recent body mass index recording. These analyses were further adjusted for calendar year and age at the newly defined index date (along with all other confounders).

Our power analysis demonstrated a power of 88%, assuming a relative risk of 1.6, a type I probability of 0.05, and based on our cohort sizes (2079 bariatric surgery patients, with an average of 5.02 matched controls per patient, and a fracture probability in the control group of 2.0%).

Results
=======

Baseline characteristics
------------------------

Table 1[](#tbl1){ref-type="table"} shows baseline characteristics of bariatric surgery patients and matched controls. We identified 2079 patients who underwent bariatric surgery (mean age 44.6 years, 83.9% female patients, mean body mass index 43.2), and a total of 10 442 matched controls (mean age 44.9 years, 85.3%, 40.8). Adjustable gastric banding was the most frequent surgical technique for bariatric surgery (1249 (60%)), followed by Roux-en-Y gastric bypass (613 (29%), fig 1[](#fig1){ref-type="fig"}). The median difference between the index date and most recent record of body mass index was 109 days (interquartile range 241) for patients who underwent bariatric surgery and 321 days (680) for matched controls. Bariatric surgery patients were more likely to have used antidiabetics, antidepressants, anxiolytics or hypnotics, and proton pump inhibitors in the previous six months. Total duration of follow-up was 28 899 person years (mean 2.2 years for bariatric surgery patients and 2.3 years for matched controls).

###### 

 Baseline characteristics of bariatric surgery patients and controls matched by age, sex, and body mass index. Data are no (%) of patients unless stated otherwise

  Characteristic                        Bariatric surgery patients (n=2079)   Matched controls (n=10 442)
  ------------------------------------- ------------------------------------- -----------------------------
  Follow-up time (years)\*              2.2 (2.1)                             2.3 (2.2)
  Female patients                       1744 (83.9)                           8904 (85.3)
  Age at index date (years)\*           44.6 (11.1)                           44.9 (11.2)
  Body mass index at index date\*       43.2 (7.2)                            40.8 (6.4)
  Smoking status                                                              
   Never                                1092 (52.5)                           5957 (57.0)
   Current                              377 (18.1)                            2293 (22.0)
   Ex-smoker                            591 (28.4)                            2100 (20.1)
   Unknown                              19 (0.9)                              92 (0.9)
  Falls (within previous 6-12 months)   22 (1.1)                              58 (0.6)
  History of disease ever before                                              
   Fracture                             407 (19.6)                            1876 (18.0)
   Rheumatoid arthritis                 30 (1.4)                              120 (1.1)
   Cerebrovascular disease              37 (1.8)                              156 (1.5)
  Drug use within previous 6 months                                           
   Glucocorticoids                      89 (4.3)                              370 (3.5)
   Calcium or vitamin D supplements     104 (5.0)                             174 (1.7)
   Antiobesity drugs                    248 (11.9)                            576 (5.5)
   Antidiabetics                        401 (19.3)                            1102 (10.6)
   Antidepressants                      697 (33.5)                            2050 (19.6)
   Anxiolytics or hypnotics             203 (9.8)                             574 (5.5)
   Bisphosphonates                      8 (0.4)                               68 (0.7)
   Hormone replacement therapy          90 (4.3)                              271 (2.6)
   Proton pump inhibitors               503 (24.2)                            1315 (12.6)

\*Data are mean (standard deviation).

![**Fig 1** Number of bariatric surgery procedures performed between 1990 and 2010, by year and type of bariatric surgery](lala004608.f1_default){#fig1}

Overall risk of fracture
------------------------

Table 2[](#tbl2){ref-type="table"} shows the overall risk of fracture in bariatric surgery patients compared with matched controls, stratified by fracture type. We did not observe an increase in overall risk for any fracture (8.8 *v* 8.2 per 1000 person years; adjusted relative risk 0.89, 95% confidence interval 0.60 to 1.33), osteoporotic fracture (0.67, 0.34 to 1.32), or non-osteoporotic fracture (0.90, 0.56 to 1.45). Similar rates for any fracture were observed throughout the different surgical techniques.

###### 

 Risk of fracture in bariatric surgery patients compared with controls matched by age, sex, and body mass index, by type of fracture

                                         Fracture (no (%))   Crude relative risk (95% CI)\*   Adjusted relative risk (95% CI)†
  -------------------------------------- ------------------- -------------------------------- ----------------------------------
  No bariatric surgery                   207 (2.0)           Reference                        Reference
  Any fracture after bariatric surgery   38 (1.8)            1.07 (0.74 to 1.54)              0.89 (0.60 to 1.33)
  Type of bariatric surgery                                                                   
   Gastric banding                       21 (1.0)            0.85 (0.53 to 1.36)              0.82 (0.50 to 1.36)
   Roux-en-Y gastric bypass              9 (0.4)             2.11 (0.98 to 4.56)              0.77 (0.27 to 2.16)
   Other                                 8 (0.4)             1.24 (0.51 to 3.01)              1.28 (0.42 to 3.92)
  Type of fracture                                                                            
   Non-osteoporotic                      26 (1.3)            1.01 (0.65 to 1.57)              0.90 (0.56 to 1.45)
   Osteoporotic                          13 (0.6)            0.88 (0.47 to 1.64)              0.67 (0.34 to 1.32)

\*Adjusted for age, sex, and most recent record of body mass index before the index date.

†Adjusted for age, sex, and most recent record of body mass index before the index date; a history of fracture, inflammatory bowel disease, and cerebrovascular disease ever before; a history of falls in the previous 6-12 months; and use of glucocorticoids, calcium or vitamin D supplements, antiobesity drugs, antihypertensive drugs, loop diuretics, organic nitrates, antidepressants, anxiolytics or hypnotics, bisphosphonates, opioids (tramadol or stronger), and proton pump inhibitors in the previous six months.

Figure 2[](#fig2){ref-type="fig"} and table 3[](#tbl3){ref-type="table"} demonstrate the change in adjusted relative risk with time after surgery, showing a modestly increased risk over the first three months, followed by a reduction and then a trend towards increasing fracture risk after three to five years. However, none of these trends achieved statistical significance, and overall there was no significant interaction between bariatric surgery and time. Our sensitivity analysis showed similar findings when we restricted the sets to bariatric surgery with only recent records of body mass index. Table 2 lists confounders that were included in the final adjusted models.

![**Fig 2** Spline regression plot of time since bariatric surgery and risk of any fracture in bariatric surgery patients versus matched controls. Risk adjusted for confounders as shown in table 2](lala004608.f2_default){#fig2}

###### 

 Risk of any fracture in bariatric surgery patients and matched controls over time

  Time since index date (months)   Bariatric surgery patients   Matched controls                                      
  -------------------------------- ---------------------------- ------------------ ------ ------ -------- ---- ------ ------
  0-3                              2079                         5                  493    1.01   10 442   20   2619   0.76
  4-12                             1916                         12                 1225   0.98   9733     55   6622   0.83
  13-24                            1393                         9                  1119   0.80   7255     49   6191   0.79
  25-60                            888                          8                  1357   0.59   4717     63   7577   0.83
  \>60                             170                          4                  337    1.19   1003     20   2200   0.91

\*Calculated as the number of events divided by the number of person years in each period.

Risk factors for fracture in bariatric surgery patients
-------------------------------------------------------

For bariatric surgery patients, use of anxiolytics in the previous six months (adjusted relative risk 1.82, 95% confidence interval 1.06 to 3.15), and a history of cerebrovascular disease (8.26, 4.40 to 15.52) or previous fracture (2.44, 1.59 to 3.76) raised the risk of fracture. Use of antidepressants, antidiabetics, proton pump inhibitors, or statins within six months did not significantly alter fracture risk within these patients (data not shown).

Influence of excess reduction in body mass index after surgery
--------------------------------------------------------------

Although we saw a trend towards an increased risk of fracture with greater reduction of excess body mass index after surgery, this was not significant (table 4[](#tbl4){ref-type="table"}). However, this analysis had limited statistical power. Thus, compared with patients with a medium excess loss in body mass index (1-50%), the adjusted relative risk was 0.32 (95% confidence interval 0.04 to 2.57) in those with no excess loss in body mass index, and 1.46 (0.55 to 3.85) in those who lost over 50% of their excess body mass index. The association between body mass index loss and fracture risk remained similar after we included only patients with a body mass index recording in the two months before bariatric surgery.

###### 

 Risk of any fracture in bariatric surgery patients, by excess body mass index change during follow-up

                                         Any fracture (no (%))   Crude relative risk (95% CI)\*   Adjusted relative risk (95% CI)†
  -------------------------------------- ----------------------- -------------------------------- ----------------------------------
  Any fracture after bariatric surgery   38 (1.8)                ---                              ---
  Excess loss in body mass index                                                                  
   \<0%                                  1 (0.0)                 0.31 (0.04 to 2.49)              0.32 (0.04 to 2.57)
   0-50%                                 9 (0.4)                 Reference                        Reference
   \>50%                                 8 (0.4)                 1.58 (0.61 to 4.11)              1.46 (0.55 to 3.85)
   Unknown                               20 (1.0)                0.56 (0.25 to 1.25)              0.51 (0.23 to 1.15)

\*Adjusted for age, sex, and most recent record of body mass index before the index date.

†Adjusted for confounders as shown in table 2.

Discussion
==========

To our knowledge, this is the first study to investigate fracture risk in patients who underwent bariatric surgery versus matched controls. Although we observed a possible rise in fracture risk at three to five years after surgery, overall, we were not able to demonstrate a significantly increased risk of any, non-osteoporotic, or osteoporotic fracture with bariatric surgery. We saw a trend towards increasing fracture risk with greater magnitude of excess reduction in body mass index after bariatric surgery, but again, this was not significant.

Comparison with other studies
-----------------------------

Although no fracture studies have compared bariatric surgery patients with matched controls so far, our findings are indirectly supported by a meta-analysis by De Laet and colleagues.[@ref39] They showed that a decrease in body mass index was less predictive of fracture in obese patients (\>30) than in those with a body mass index of less than 30. For example, when comparing patients with a body mass index of 15 and 20, the researchers found a 3.7-fold elevated risk of hip fracture in the leaner patients. However, when comparing those with a body mass index of 30 and 35, the relative risk was much lower (non-significant 1.1-fold increase in leaner patients). The authors suggested that leanness is a much more important risk factor for fracture, rather than considering obesity as a protective factor. A study by Nakamura and colleagues estimated fracture rates in bariatric surgery patients, but could not compare this group with controls matched by body mass index.[@ref40] Although they do suggest an increased risk based on expected age and sex specific incidence, this difference may well be the effect of obesity related comorbidities (as we have shown in our baseline characteristics).

So far, studies on bariatric surgery and bone effects have been limited to a number of reports on bone resorption markers and bone mineral density.[@ref10] [@ref14] [@ref15] [@ref16] [@ref17] [@ref18] [@ref19] [@ref21] [@ref22] [@ref23] [@ref24] [@ref25] [@ref26] [@ref27] Although the effect seemed to be small and varied between studies, the results suggested that bariatric surgery might negatively affect bone outcomes. For example, Giusti and colleagues reported a slight decrease in bone mineral density at the femoral neck (−5.8%), trochanter (−6.5%), but not at the lumbar spine (+8.0%), two years after gastric banding procedures.[@ref6] Similarly, Guney and colleagues showed a 9.9% drop in bone mineral density at the femoral neck, one year after vertical banded gastroplasty.[@ref6] [@ref10] The detrimental effect on bone seemed to be less apparent with malabsorptive procedures. Ten years after biliopancreatic diversion, a 4.2% decrease in spinal bone mineral density was found, but no significant change in hip bone mineral density.[@ref16] For the Roux-en-Y gastric bypass, a combined restrictive and malabsorptive procedure, decreases in femoral bone mineral density were found to be as low as 3.5% after two years,[@ref23] and as high as 10% after one year.[@ref27]

The reduction in bone mineral density after bariatric surgery may have several biological mechanisms. Firstly, a fall in bone active adipocyte hormones (oestrogen and leptin) following bariatric surgery may initiate bone loss. Oestrogen depletion has been associated with vertical banded gastroplasty (22% reduction after one year),[@ref10] and is strongly linked to bone loss in perimenopausal women.[@ref41] Decreased leptin levels as a result of weight loss could enhance osteoclast activity and therefore initiate bone loss,[@ref12] [@ref13] and alter the balance between osteoblast and adipocyte formation.

Secondly, lowered levels of insulin and amylin could follow weight loss, resulting in enhanced osteoclast recruitment and inhibition of osteoblast activity.[@ref12] Thirdly, although evidence is conflicting, malabsorptive procedures could be linked with calcium and vitamin D deficiency (both are associated with a decrease in bone mineral density and increased fracture risk).[@ref42] Since malabsorptive procedures (including combined restrictive or malabsorptive procedures, such as the Roux-en-Y gastric bypass) are more likely to lead to malnutrition (hypocalcaemia) and vitamin deficiencies than restrictive procedures (for example, gastric banding),[@ref43] risk of fracture could differ between these surgical techniques. Although limited in statistical power, our study did not observe such a difference in fracture risk between gastric banding and Roux-en-Y gastric bypass. Finally, the effect of bariatric surgery on bone might also depend not only on the type of surgical procedure itself, but also on the degree of sarcopenia caused or accelerated by marked weight loss.

Alternatively, the observed decrease in bone mineral density might be explained by measurement errors of bone mineral density in morbidly obese patients.[@ref6] Variability of bone mineral density rises substantially when soft tissue depths exceed 25 cm.[@ref44] Moreover, Madsen and colleagues showed that fat around bone could falsely increase measured levels of bone mineral density.[@ref45] As a consequence, reported falls in bone mineral density at femoral and trochanter sites after bariatric surgery could have been overestimated.

Strengths and limitations of the study
--------------------------------------

Our study has several strengths. To the best of our knowledge, this is the first cohort of bariatric surgery patients in which the risk of fracture has been investigated. We had a statistical power of 88% to detect a relative risk of at least 1.6. Our data sources had detailed longitudinal information on drug prescribing and other risk factors for fracture, such as smoking status. Furthermore, since 2004, body mass index is very well registered within the Clinical Practice Research Datalink (\>85%), which is a result of the introduction of the Quality Outcomes Framework in 2004. This allowed us to match controls by body mass index accurately, which is important given the association between body weight and bone mineral density.[@ref12]

A major limitation of this study was that body mass index was not routinely collected over short time intervals. We therefore selected the most recent recording of body mass index, assuming this information has not substantially changed over time (before surgery). This lack of data also limited our statistical power in the analysis evaluating the influence of excess reduction in body mass index. Therefore, it was not possible to draw definite conclusions about the role of the magnitude of reduction in body mass index after bariatric surgery. Although obese patients probably change weight continuously, and we did not have information on body mass index at the exact day of bariatric surgery, restricting the study population to those with records in the previous two months did not substantially change the results. Furthermore, the Clinical Practice Research Datalink describes events that occurred or were recorded in general practice. Events occurring in secondary or intermediary services could therefore be incompletely ascertained. In addition, we did not have information on bone mineral density, which could have been useful for determining the underlying biological mechanism in the association between bariatric surgery and fracture.

We cannot exclude the possibility of confounding by (contra)indication in this study. The National Institute for Health and Clinical Excellence guidelines recommend bariatric surgery in morbidly obese patients, preferably with coexisting diseases (for example, type 2 diabetes and hypertension) that could be improved by weight loss.[@ref43] We did not have information on whether patients were considered for bariatric surgery and then did not undergo an operation because of lack of associated comorbidities. However, since these comorbidities were probably not associated with reduced fracture rate, it is unlikely that this consideration would reduce our ability to detect a difference in fracture rate between bariatric surgery and control patients.

Although a possibility of residual confounding due to unmeasured unbalances between the two study groups still exists, controls in this study seemed to be healthier (with fewer obesity related comorbidities) than patients who underwent bariatric surgery, and could therefore not have masked a true association between bariatric surgery and fracture. Furthermore, poor general fitness (associated with a loss in bone mineral density) may be a reason to not undergo bariatric surgery. Sjöström and colleagues showed that bariatric surgery patients were more physically active than obese controls.[@ref46] Although we adjusted for factors such as hypertension and use of glucose lowering drugs, we could not adjust for physical activity. However, this healthy user bias would have probably resulted in a decreased fracture risk shortly after surgery, whereas we found a trend towards the opposite. It is usual for patients to modify their diet before surgery to reduce the fat and glycogen content of the liver. This diet may be based on solid or liquid foods. We did not have information on perioperative diet, and therefore were not able to adjust for this potential confounder, but feel that such dietary change over the period of a few weeks would be unlikely to substantially alter fracture risk, particularly because the diet is aimed to preserve muscle tissue.

We used a widely accepted definition of osteoporotic and non-osteoporotic fracture types, but it is difficult to be sure about fracture cause based simply on fracture site, with no information on the level of trauma. Finally, we had a relatively short follow-up time (median time 2.2 years for bariatric surgery patients), which yielded a reduced power to exclude an increase in fracture risk beyond five years.

### What is already known on this topic

1.  Bariatric surgery can be considered among patients with morbid obesity

2.  Bariatric surgery has been linked to a reduction in bone mineral density, although fracture rates compared with matched controls are unknown

### What this study adds

1.  Bariatric surgery does not have a significant effect on fracture risk

2.  However, there could be an increase in risk after three to five years and in patients who have a greater decrease in body mass index after surgery
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